Cirevetmab, a novel canine anti–TGFβ monoclonal antibody, exerts antifibrotic effects on renal cells in vitro
Dayna L. Kappenman, Christopher L. Koehler, Reese N. Prentice, Nadia Koziar, Andrew Beardow, Alexandre Merlo, Christopher S. Knauer, Duncan Mwangi, Catrina Stirling · 2026
Read Cirevetmab, a novel canine anti–TGFβ monoclonal antibody, exerts antifibrotic effects on renal cells in vitro by Dayna L. Kappenman, Christopher L. Koehler, Reese N. Prentice, Nadia Koziar, Andrew Beardow, Alexandre Merlo, Christopher S. Knauer, Duncan Mwangi, Catrina Stirling (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585715.txt.
Description
Dayna Kappenman and eight co-authors test cirevetmab, a new antibody drug for dogs, against a growth factor that drives kidney scarring. Chronic kidney disease is common in dogs and closely resembles the human illness. The growth factor TGF-beta, in three forms, helps push the disease forward, yet targeted treatments for dogs are barely explored.
The team worked with kidney tubule cells from dogs and humans in the lab. All three forms of the factor switched on the scarring pathway in the cells, raising a marker protein tied to fibrosis. Cirevetmab strongly blocked the first form's effects, both on the pathway signal and on the scarring markers. It partly blocked the third form's signal but not its markers, and it did nothing against the second form. The authors present the drug as a selective blocker with promise for canine kidney disease.
Catalog record
| CREATOR | Dayna L. Kappenman, Christopher L. Koehler, Reese N. Prentice, Nadia Koziar, Andrew Beardow, Alexandre Merlo, Christopher S. Knauer, Duncan Mwangi, Catrina Stirling |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |